Connor, Clark & Lunn Investment Management (CC&L)
AVXL icon

Connor, Clark & Lunn Investment Management (CC&L)’s Anavex Life Sciences AVXL Stock Holding History

Connor, Clark & Lunn Investment Management (CC&L)’s Portfolio AVXL Stock Details AVXL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$60.3K Buy
+19,655
New +$85.1K ﹤0.01% 1515
2022
Q4 		– Sell
-96,927
Closed -$1M – 1202
2022
Q3 		$1M Buy
96,927
+80,005
+473% +$844K 0.01% 656
2022
Q2 		$169K Buy
+16,922
New +$160K ﹤0.01% 950

Other funds holding AVXL

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
SF
Summit Financial Parsippany, New Jersey $7.85B AUM 20.99% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Connor, Clark & Lunn Investment Management (CC&L)'s AVXL Position: Q1 2026 in Review

Connor, Clark & Lunn Investment Management (CC&L) opened a new position in Anavex Life Sciences (AVXL) in Q1 2026: 19,655 shares worth $60.3K. The stake represents ﹤0.01% of the portfolio and ranks #1515 among its holdings. This is a return to the name: Connor, Clark & Lunn Investment Management (CC&L) previously reported a position in AVXL as recently as Q3 2022.

Connor, Clark & Lunn Investment Management (CC&L) first reported a position in AVXL in Q2 2022 and has held it in 3 quarters since. The position peaked at $1M in Q3 2022. 190 funds tracked by Wall St. Rank hold AVXL as of Q1 2026.

  • Connor, Clark & Lunn Investment Management (CC&L) held 19,655 shares of Anavex Life Sciences worth $60.3K as of Q1 2026.
  • Anavex Life Sciences was a new Connor, Clark & Lunn Investment Management (CC&L) position in Q1 2026.
  • Anavex Life Sciences made up ﹤0.01% of Connor, Clark & Lunn Investment Management (CC&L)'s portfolio in Q1 2026, its #1515 holding.
  • Connor, Clark & Lunn Investment Management (CC&L) first reported a position in Anavex Life Sciences in Q2 2022 and has held it in 3 quarters since.
  • Connor, Clark & Lunn Investment Management (CC&L)'s Anavex Life Sciences position peaked at $1M in Q3 2022.
  • 190 funds tracked by Wall St. Rank held Anavex Life Sciences as of Q1 2026.

Based on Connor, Clark & Lunn Investment Management (CC&L)'s 13F filing for Q1 2026, filed 11 May 2026.